The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors.
 
Roisin O'Cearbhaill
Honoraria - Aptitude Health; Curio Science; GlaxoSmithKline; GOG Foundation; MJH/PER
Consulting or Advisory Role - 2seventy bio; GlaxoSmithKline; GOG Foundation; Immunogen; Loxo/Lilly; Miltenyi Biotec; Regeneron; Seagan; Takeda Science Foundation
Research Funding - Acrivon Therapeutics (Inst); ArsenalBio (Inst); AstraZeneca/Merck (Inst); Atara Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Context Therapeutics (Inst); Debiopharm Group (Inst); Genentech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); GOG Foundation (Inst); Juno Therapeutics (Inst); Kite/Gilead (Inst); Ludwig Institute for Cancer Research (Inst); Lyell Immunopharma (Inst); Merck/Genentech (Inst); Mural Oncology (Inst); OnCusp Therapeutics (Inst); Regeneron (Inst); Sellas Life Sciences (Inst); Syndax (Inst); TapImmune Inc. (Inst); TCR2 Therapeutics (Inst)
Travel, Accommodations, Expenses - Gathering Around Cancer; Society of Gynecologic Oncology
Other Relationship - JAMA Oncology
 
Minal Barve
Employment - Texas Oncology
Stock and Other Ownership Interests - Texas Oncology
Research Funding - SCRI at Mary Crowley Cancer Research
 
Christopher Darus
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Zentalis
 
Nashat Gabrail
Consulting or Advisory Role - Celgene; Chemiocare
Speakers' Bureau - Janssen Oncology; Janssen Oncology; Janssen Oncology; Karyopharm Therapeutics; Taiho Pharmaceutical; Taiho Pharmaceutical; Tesaro/GSK
Research Funding - Amgen (Inst); Bayer (Inst); Chemiocare (Inst); Chemiocare (Inst); Kartos Therapeutics (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Oncology Supply
 
Paul Johannet
No Relationships to Disclose
 
Jade Loh
No Relationships to Disclose
 
MaryBeth LeRose
No Relationships to Disclose
 
Karen Andreas
No Relationships to Disclose
 
Claudio Dansky Ullmann
No Relationships to Disclose